Thinkzone Network: Taizhou Life Sciences Enterprises - 2
In the last blog, we introduced three listed companies, JIUZHOU Pharmaceutical, HISOAR and Ausun. In this article, we will continue to introduce two listed pharmaceutical companies and two fast-growing companies in Taizhou.
MAIDER MEDICAL INDUSTRY EQUIPMENT CO.,LTD (Maider medical, stock code: 688310. SH) was founded in March 2003 and listed on Science and Technology Innovation Board of Shanghai Stock Exchange in December 2019. It is the first enterprise listed on Science and Technology Innovation board in Taizhou. Focusing on the R&D, Production, Sales and Service of medical consumables intelligent equipment, the company is a leading enterprise in domestic medical consumables intelligent equipment, recognized as the "Invisible Champion" enterprise in Zhejiang Province, and the first batch of specialized and new "Small Giant Enterprises" by the Ministry of industry and Information Technology in 2019. The company has a registered capital of 83.6 million yuan, an area of 50 mu, and building area of 25000 square meters, and a medical intelligent manufacturing key enterprise research institute in Zhejiang Province. The company is a patent demonstration enterprise in Zhejiang Province, with 154 invention patents, 60 utility model patents, 1 design patent, 18 software copyrights, ranking 34th among the top 100 creative enterprises in Zhejiang Province.
Maider is interested in investment on projects that are medical device, automation equipment, medical consumables, coating products, insulin pumps and dynamic blood glucose meters. The investment size ranges from 10 million yuan to 100 million yuan.
Zhe Jiang LEPU Pharmaceuticals
ZHEJIANG LEPU PHARMACEUTICAL CO.,LTD was founded in 2001. The company covers an area of nearly 300 mu, and is mainly engaged in the research and development, production and sales of anti-infection, anti-tumor, cardiovascular and nervous system, and other series of drugs. Its leading products include norfloxacin, atorvastatin, rosuvastatin, hydrochloric acid Sertraline and other APIs and preparations. It has successively passed GMP certifications including US FDA, EU COS, Japan PMDA, South Korea FFDA, etc., and many products are in the leading position in the world. LEPU’s ecosystem of cardiovascular health equipment + medicines + medical services + medical technology has been formed, and the pharmaceutical business is the largest business.
LEPU focuses on the synthesis and generic drugs technology, and is also interested in the projects related to the company's manufacturing line. At present, LEPU prefers companies post-clinical trial phase 3.
Multinpharma was established in September 2017 and is dedicated to pharmaceutical and chemical manufacturing technical services, CRO customization, continuous flow micro-reaction technology services and providing overall solutions for micro-reaction equipment. As an innovation-driven company, Multinpharma has developed more than 30 pharmaceutical intermediates.
Multinpharma’s current projects include the industrialization of salicylic acid, EPOXY series of environmentally friendly epoxy resin products, and dextromethorphan series of drugs.
Speaking of the reasons to choose Taizhou, Multinpharma said Taizhou has a good chemical industry environment and the team also meets the talent requirements. At the same time, the company has been cooperating with Xianju Pharma. It is a natural choice to land in Taizhou.
PUJI focuses on solving drug quality, safety, and environmental protection issues facing the pharmaceutical industry. It has completed core technology R&D of 20 products. These technologies are mostly improved new drugs and first generic drugs in the United States and China for cardiovascular, cancer, neurological, and rare diseases.
PUJI was founded by a group of researchers returning China in 2012. In eight years, it has invested more than 80 million in R&D. In 2015, it completed an angel round financing of 15 million yuan led by Yijin Capital. The two new drug projects for refractory hypertension (SJ038) treatment and Alzheimer's disease (X001) treatment have received a lot of attention. Due to the demand for production expansion, the company landed in Taizhou in 2016. In 2019, a targeted drug for cardiovascular disease was approved by the FDA (generic drug). The company is expected to be officially listed in 2021.
The main reason for PUJI to choose Taizhou is that Taizhou is a national API base with a high concentration of raw materials and industry resources. The local business environment is a good match for the company's development.